Literature DB >> 24520540

Modulation of immune response in experimental Chagas disease.

Beatriz Basso1.   

Abstract

Trypanosoma cruzi (T. cruzi), the etiological agent of Chagas disease, affects nearly 18 million people in Latin America and 90 million are at risk of infection. The parasite presents two stages of medical importance in the host, the amastigote, intracellular replicating form, and the extracellular trypomastigote, the infective form. Thus infection by T. cruzi induces a complex immune response that involves effectors and regulatory mechanisms. That is why control of the infection requires a strong humoral and cellular immune response; hence, the outcome of host-parasite interaction in the early stages of infection is extremely important. A critical event during this period of the infection is innate immune response, in which the macrophage's role is vital. Thus, after being phagocytized, the parasite is able to develop intracellularly; however, during later periods, these cells induce its elimination by means of toxic metabolites. In turn, as the infection progresses, adaptive immune response mechanisms are triggered through the TH1 and TH2 responses. Finally, T. cruzi, like other protozoa such as Leishmania and Toxoplasma, have numerous evasive mechanisms to the immune response that make it possible to spread around the host. In our Laboratory we have developed a vaccination model in mice with Trypanosoma rangeli, nonpathogenic to humans, which modulates the immune response to infection by T. cruzi, thus protecting them. Vaccinated animals showed an important innate response (modulation of NO and other metabolites, cytokines, activation of macrophages), a strong adaptive cellular response and significant increase in specific antibodies. The modulation caused early elimination of the parasites, low parasitaemia, the absence of histological lesions and high survival rates. Even though progress has been made in the knowledge of some of these mechanisms, new studies must be conducted which could target further prophylactic and therapeutic trials against T. cruzi infection.

Entities:  

Keywords:  Chagas disease; Innate and adaptive immune response; Trypanosoma cruzi

Year:  2013        PMID: 24520540      PMCID: PMC3905588          DOI: 10.5493/wjem.v3.i1.1

Source DB:  PubMed          Journal:  World J Exp Med        ISSN: 2220-315X


  66 in total

Review 1.  Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens.

Authors:  Manuel T Silva
Journal:  J Leukoc Biol       Date:  2010-01-28       Impact factor: 4.962

2.  Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection.

Authors:  I A Abrahamsohn; R L Coffman
Journal:  Exp Parasitol       Date:  1996-11       Impact factor: 2.011

Review 3.  Trypanosoma cruzi-induced molecular mimicry and Chagas' disease.

Authors:  N Gironès; H Cuervo; M Fresno
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

Review 4.  Chagas disease.

Authors:  A R L Teixeira; N Nitz; M C Guimaro; C Gomes; C A Santos-Buch
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

5.  Differential impact of metacyclic and blood trypomastigotes on parasitological, serological and phenotypic features triggered during acute Trypanosoma cruzi infection in dogs.

Authors:  Cláudia Martins Carneiro; Olindo Assis Martins-Filho; Alexandre Barbosa Reis; Vanja Maria Veloso; Flávio Marcos Gomes Araújo; Maria Terezinha Bahia; Marta de Lana; George Luiz Lins Machado-Coelho; Giovanni Gazzinelli; Rodrigo Correa-Oliveira; Washington Luiz Tafuri
Journal:  Acta Trop       Date:  2007-01-10       Impact factor: 3.112

6.  Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection.

Authors:  Beatriz Basso; Edgardo Moretti; Ricardo Fretes
Journal:  Mem Inst Oswaldo Cruz       Date:  2008-06       Impact factor: 2.743

Review 7.  L-arginine metabolism during interaction of Trypanosoma cruzi with host cells.

Authors:  Gonzalo Peluffo; Lucía Piacenza; Florencia Irigoín; María Noel Alvarez; Rafael Radi
Journal:  Trends Parasitol       Date:  2004-08

8.  Molecular basis of Trypanosoma cruzi-induced immunosuppression. Altered expression by activated human lymphocytes of molecules which regulate antigen recognition and progression through the cell cycle.

Authors:  F Kierszenbaum; E Moretti; M B Sztein
Journal:  Biol Res       Date:  1993       Impact factor: 5.612

9.  The exit of Trypanosoma cruzi from the phagosome is inhibited by raising the pH of acidic compartments.

Authors:  V Ley; E S Robbins; V Nussenzweig; N W Andrews
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

10.  Modulation of CD4(+) T cell-dependent specific cytotoxic CD8(+) T cells differentiation and proliferation by the timing of increase in the pathogen load.

Authors:  Fanny Tzelepis; Pedro M Persechini; Mauricio M Rodrigues
Journal:  PLoS One       Date:  2007-04-25       Impact factor: 3.240

View more
  16 in total

1.  MicroRNA-155 Deficiency Exacerbates Trypanosoma cruzi Infection.

Authors:  Bijay K Jha; Sanjay Varikuti; Abhay R Satoskar; Bradford S McGwire; Gabriella R Seidler; Greta Volpedo
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

2.  Administration of artinm lectin reduces the severity of the acute phase infection with Trypanosoma cruzi.

Authors:  Camila Botelho Miguel; Thiago Aparecido da Silva; Wellington Francisco Rodrigues; Patrícia Kellen Martins Oliveira-Brito; Maria Cristina Roque-Barreira; Javier Emílio Lazo-Chica
Journal:  FASEB Bioadv       Date:  2021-01-25

3.  Corynebacterium pseudotuberculosis cp09 mutant and cp40 recombinant protein partially protect mice against caseous lymphadenitis.

Authors:  Judson W Silva; Daniela Droppa-Almeida; Sibele Borsuk; Vasco Azevedo; Ricardo W Portela; Anderson Miyoshi; Flávia S Rocha; Fernanda A Dorella; Wanessa L Vivas; Francine F Padilha; Maria L Hernández-Macedo; Isabel B Lima-Verde
Journal:  BMC Vet Res       Date:  2014-12-20       Impact factor: 2.741

4.  BALB/c and C57BL/6 Mice Cytokine Responses to Trypanosoma cruzi Infection Are Independent of Parasite Strain Infectivity.

Authors:  Bianca L Ferreira; Éden R Ferreira; Marlon V de Brito; Bruno R Salu; Maria L V Oliva; Renato A Mortara; Cristina M Orikaza
Journal:  Front Microbiol       Date:  2018-03-26       Impact factor: 5.640

Review 5.  The Role of Co-Stimulatory Molecules in Chagas Disease.

Authors:  Bruna F Pinto; Nayara I Medeiros; Tereza C M Fontes-Cal; Isabela M Naziazeno; Rodrigo Correa-Oliveira; Walderez O Dutra; Juliana A S Gomes
Journal:  Cells       Date:  2018-11-07       Impact factor: 6.600

6.  Age-Related Differential Stimulation of Immune Response by Babesia microti and Borrelia burgdorferi During Acute Phase of Infection Affects Disease Severity.

Authors:  Vitomir Djokic; Shekerah Primus; Lavoisier Akoolo; Monideep Chakraborti; Nikhat Parveen
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

7.  Vesicles from different Trypanosoma cruzi strains trigger differential innate and chronic immune responses.

Authors:  Paula M Nogueira; Kleber Ribeiro; Amanda C O Silveira; João H Campos; Olindo A Martins-Filho; Samantha R Bela; Marco A Campos; Natalia L Pessoa; Walter Colli; Maria J M Alves; Rodrigo P Soares; Ana Claudia Torrecilhas
Journal:  J Extracell Vesicles       Date:  2015-11-26

8.  Exacerbated skeletal muscle inflammation and calcification in the acute phase of infection by Mexican Trypanosoma cruzi DTUI strain.

Authors:  Andrea Vizcaíno-Castillo; Andrea Jiménez-Marín; Bertha Espinoza
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

9.  Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by Enhancing Parasitism, Inflammation, and Reactive Tissue Damage in Trypanosoma cruzi-Infected Mice.

Authors:  Rômulo D Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Andréa A S Mendonça; Eduardo de Almeida Marques-da-Silva; Sílvia A Cardoso; Juliana L R Fietto; Leandro L Oliveira
Journal:  Oxid Med Cell Longev       Date:  2018-09-30       Impact factor: 6.543

10.  Correlation of Parasite Burden, kDNA Integration, Autoreactive Antibodies, and Cytokine Pattern in the Pathophysiology of Chagas Disease.

Authors:  Moisés Wesley; Aline Moraes; Ana de Cássia Rosa; Juliana Lott Carvalho; Tatiana Shiroma; Tamires Vital; Nayra Dias; Bruna de Carvalho; Doralina do Amaral Rabello; Tatiana Karla Dos Santos Borges; Bruno Dallago; Nadjar Nitz; Luciana Hagström; Mariana Hecht
Journal:  Front Microbiol       Date:  2019-08-21       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.